Date | Time | Source | Announcement |
---|---|---|---|
12 Dec 2005 | 11:24 AM | Result of EGM | |
09 Dec 2005 | 11:43 AM | Holding(s) in Company | |
08 Dec 2005 | 03:31 PM | Holding(s) in Company | |
24 Nov 2005 | 11:37 AM | Holding(s) in Company | |
22 Nov 2005 | 04:12 PM | Blocklisting Interim Review | |
22 Nov 2005 | 12:17 PM | Holding(s) in Company | |
22 Nov 2005 | 07:00 AM | TroVax Notice of Allowance | |
17 Nov 2005 | 09:35 AM | Holding(s) in Company | |
16 Nov 2005 | 04:20 PM | Publication of Prospectus | |
16 Nov 2005 | 07:01 AM | Phase II trial with TroVax | |
16 Nov 2005 | 07:01 AM | Placing and Open Offer | |
15 Nov 2005 | 11:54 AM | Holding(s) in Company | |
02 Nov 2005 | 02:22 PM | Trovax & Proposed Fundraising | |
24 Oct 2005 | 01:49 PM | Trovax Clarification | |
24 Oct 2005 | 07:00 AM | Licence Agreement | |
20 Oct 2005 | 07:00 AM | Agreement with Sigma-Aldrich | |
19 Oct 2005 | 07:00 AM | Wyeth Preclinical Data | |
18 Oct 2005 | 11:30 AM | Additional Phase II Data | |
17 Oct 2005 | 07:00 AM | Final Phase II Results | |
06 Oct 2005 | 07:00 AM | Prelim Phase II Results | |
03 Oct 2005 | 01:54 PM | Change of Adviser | |
28 Sep 2005 | 05:55 PM | Holding(s) in Company | |
20 Sep 2005 | 07:00 AM | Interim Results | |
16 Sep 2005 | 06:22 PM | Holding(s) in Company | |
07 Sep 2005 | 07:01 AM | Appointment | |
05 Sep 2005 | 07:00 AM | Notice of Results | |
25 Aug 2005 | 02:11 PM | Holding(s) in Company | |
18 Aug 2005 | 10:06 AM | Holding(s) in Company | |
17 Aug 2005 | 01:56 PM | Holding(s) in Company | |
01 Aug 2005 | 07:00 AM | Completion of Clinical Trial | |
25 Jul 2005 | 07:00 AM | Awarded Research Grant | |
06 Jul 2005 | 04:09 PM | Holding(s) in Company | |
04 Jul 2005 | 07:00 AM | Two New Patents Granted | |
30 Jun 2005 | 04:00 PM | Holding(s) in Company | |
29 Jun 2005 | 04:00 PM | Holding(s) in Company | |
17 Jun 2005 | 03:21 PM | Holding(s) in Company | |
17 Jun 2005 | 11:12 AM | Chair Panel at BIO 2005 | |
16 Jun 2005 | 04:47 PM | Holding(s) in Company | |
06 Jun 2005 | 03:00 PM | Director Shareholding | |
06 Jun 2005 | 07:00 AM | Licensing Agreement | |
03 Jun 2005 | 09:00 AM | Viragen Milestone | |
03 Jun 2005 | 07:00 AM | Innurex ASGT Data | |
19 May 2005 | 03:22 PM | Blocklisting Interim Review | |
16 May 2005 | 07:00 AM | Phase II trials of TroVax | |
12 May 2005 | 04:00 PM | Holding(s) in Company | |
12 May 2005 | 10:24 AM | 2005 ASCO Annual Meeting | |
10 May 2005 | 12:05 PM | AGM Statement | |
09 May 2005 | 07:00 AM | European Patent Granted | |
05 May 2005 | 07:00 AM | Preclinical Effiancy Data | |
27 Apr 2005 | 04:00 PM | Holding(s) in Company |
Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.
Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.
Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.